Established in 1992, Sciensus is a leading European provider of pharmacy-focused services, providing patient access and insight to a range of healthcare stakeholders. The company operates across the chronic, cancer and rare disease markets, working with clinicians, payors and pharmaceutical companies to optimise the health outcomes of their patients.
Since Palladian’s investment in 2019, Sciensus has undergone a comprehensive digital transformation, building a unique tech-enabled platform to manage over 200,000 patients and their biological, infused and other complex therapies. Through its services, Sciensus helps patients get the best possible benefits from their medicines, allowing them to live highly enabled lives, whilst simultaneously lowering costs for payors.
Sciensus is based in London and has operational hubs in the Netherlands and Switzerland.
“We’re very pleased to have Palladian join us as investors. They are already playing a hands on role, bringing welcome industry insight and fresh perspectives as we undergo a complete digital transformation; this will allow us to use the power of data and analytics to unlock extensive benefits for our patients, payors and pharmaceutical partners.”
Darryn Gibson, Chief Executive, Sciensus
